drugset / Trial / NCT03770689
Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer
Phase 1/2
Completed
19 enrolled
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main purpose of the study was to define maximum tolerated dose (MTD), recommended Phase II dose (RP2D) safety and tolerability of Peposertib in combination with capecitabine and radiotherapy (RT).
Timeline
- Start
- 2019-03-20
- Primary completion
- 2021-06-21
- Completion
- 2022-02-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NEDISERTIB | Small molecule | 50 mg | — |
| Subject | NEDISERTIB | Small molecule | 100 mg | — |
| Subject | NEDISERTIB | Small molecule | 150 mg | — |
| Subject | NEDISERTIB | Small molecule | 250 mg | — |
| Background | Capecitabine | Small molecule | 825 mg/m2 | — |
Indications
No indication recorded.